Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.15/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.15/Share

Eleven Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

March 24, 2017 7:00 AM EDT

-- Advancing Late-Stage Targeted Protein Therapeutics Pipeline for Treatment of Cancers with High Unmet Medical Need --

-- Completed Integration of Viventia Bio --

-- Topline Phase 3 Data for Lead Drug Candidate Vicinium, in Development for Non-Muscle Invasive Bladder Cancer, Expected in 2018 --

- Management to Host Conference Call Today at 8:00 a.m. ET -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel... More